Kura Oncology, Inc. (NASDAQ:KURA) Stock Has Average Price Target of $25.69 According to Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $25.35.

Several brokerages recently commented on KURA. Deutsche Bank Aktiengesellschaft set a $24.00 price objective on Kura Oncology in a research note on Wednesday. UBS Group reissued a “buy” rating on shares of Kura Oncology in a research note on Monday, October 5th. Raymond James Financial set a $24.00 price target on Kura Oncology in a report on Monday, August 24th. Citizens Jmp restated a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $9.70 on Friday. The company’s fifty day moving average is $11.40 and its 200-day moving average is $10.33. Kura Oncology has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. On average, equities analysts predict that Kura Oncology will post -3.25 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, CEO Troy Wilson acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was acquired at an average cost of $11.12 per share, for a total transaction of $1,112,000.00. Following the transaction, the chief executive officer owned 379,194 shares of the company’s stock, valued at $4,216,637.28. This trade represents a 35.82% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Powl sold 17,020 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.53, for a total value of $179,220.60. Following the completion of the transaction, the insider owned 152,249 shares of the company’s stock, valued at $1,603,181.97. This represents a 10.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 153,881 shares of company stock worth $1,708,183 over the last three months. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of KURA. Dimensional Fund Advisors LP increased its position in shares of Kura Oncology by 32.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after acquiring an additional 348,127 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Kura Oncology by 69.7% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after acquiring an additional 233,633 shares during the period. Great Lakes Advisors LLC acquired a new stake in shares of Kura Oncology during the second quarter worth $2,851,000. Tidal Investments LLC acquired a new stake in shares of Kura Oncology during the second quarter worth $1,029,000. Finally, Janney Montgomery Scott LLC lifted its position in Kura Oncology by 285.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock valued at $1,291,000 after acquiring an additional 117,650 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth.

Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway.

Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions.